RLAY vs. IMTX, RGNX, BCRX, CRGX, CABA, KYTX, CGEM, ADAP, SRRK, and HLVX
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Immatics (IMTX), REGENXBIO (RGNX), BioCryst Pharmaceuticals (BCRX), CARGO Therapeutics (CRGX), Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX), Cullinan Oncology (CGEM), Adaptimmune Therapeutics (ADAP), Scholar Rock (SRRK), and HilleVax (HLVX). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.
Immatics has a net margin of -179.67% compared to Relay Therapeutics' net margin of -1,263.49%. Relay Therapeutics' return on equity of -42.43% beat Immatics' return on equity.
Relay Therapeutics received 11 more outperform votes than Immatics when rated by MarketBeat users. However, 71.43% of users gave Immatics an outperform vote while only 59.02% of users gave Relay Therapeutics an outperform vote.
Relay Therapeutics currently has a consensus price target of $26.00, indicating a potential upside of 322.42%. Given Relay Therapeutics' higher possible upside, research analysts plainly believe Relay Therapeutics is more favorable than Immatics.
Immatics has higher revenue and earnings than Relay Therapeutics. Immatics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Relay Therapeutics had 4 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Relay Therapeutics and 0 mentions for Immatics. Relay Therapeutics' average media sentiment score of -0.81 beat Immatics' score of -1.00 indicating that Relay Therapeutics is being referred to more favorably in the media.
Relay Therapeutics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500.
97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 3.5% of Relay Therapeutics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Relay Therapeutics beats Immatics on 11 of the 17 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
